Press Releases

 
Press Releases
Date Title and Summary View
Aug 3, 2017 MADISON, Wis., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces that management will host a teleconference and live webcast to report second quarter 2017 financial results, followed by a review of corporate perf...
PDF
Aug 1, 2017 MADISON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the "company"), today announces the initiation of a collaboration with Avicenna Oncology GmbH, a leading precision medicine company based in Basel, Switzerland. The collaboration wil...
PDF
Jun 6, 2017 MADISON, Wis., June 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that president and CEO Jim Caruso will be presenting at 2017 Marcum MicroCap Conference on Thursday, June 15 at 11:00 AM ET. The conference will be held June 15-16 at the Grand ...
PDF
May 30, 2017 MADISON, Wis., May 30, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), an oncology-focused biotechnology company, today announced that it will be presenting at the 7th annual LD Micro Invitational on Tuesday, June 6 at 12:00 Noon PT/3:00 PM ET.  Jim Caruso, president and CEO of Cellectar, will ...
PDF
May 18, 2017 MADISON, Wis., May 18, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces preclinical data from three abstracts demonstrating the utility of the company's lead compound, CLR 131, for use in a variety of tumor types in ...
PDF
May 11, 2017 MADISON, Wis., May 11, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces financial results for first quarter of 2017.  Management will host a teleconference and live webcast to review these results, including a revi...
PDF
May 2, 2017 MADISON, Wis., May 02, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report first quarter 2017 financial results, followed by a review of corporate perform...
PDF
Apr 27, 2017 MADISON, Wis., April 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces preclinical data that demonstrate the utility of the company's lead compound, CLR 131, and CLR 125 for use in solid tumors, as well as the potent...
PDF
Apr 25, 2017 MADISON, Wis., April 25, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the United States Patent and Trademark Office has granted a method of use patent for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrrome...
PDF
Apr 21, 2017 MADISON, Wis., April 21, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces it has appointed John Friend, II, M.D. as vice president and chief medical officer effective April 17, 2017. "Cellectar has accelerated and expanded ...
PDF
Page: FirstPrevious
3
... NextLast